Literature DB >> 23918819

Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.

Rajareddy Singareddy1, Louie Semaan, M Katie Conley-Lacomb, Jason St John, Katelyn Powell, Matthew Iyer, Daryn Smith, Lance K Heilbrun, Dongping Shi, Wael Sakr, Michael L Cher, Sreenivasa R Chinni.   

Abstract

UNLABELLED: CXCR4 is a chemokine receptor that mediates invasion and metastasis. CXCR4 expression is transcriptionally regulated in cancer cells and is associated with aggressive prostate cancer phenotypes. Previously, we and others have shown that the transcription factor ERG regulates CXCR4 expression in prostate cancer cells and that androgens modulate CXCR4 expression via increasing ERG expression. Herein, the molecular mechanisms of ERG-mediated CXCR4 promoter activation, phosphorylation of ERG by intracellular kinases and subsequent CXCR4 expression, as well as the status of ERG and CXCR4 in human prostate cancer specimens were investigated. Using multiple molecular strategies, it was demonstrated that (i) ERG expressed in TMPRSS2-ERG fusion positive VCaP cells selectively binds to specific ERG/Ets bindings sites in the CXCR4 promoter; (ii) distal binding sites mediate promoter activation; (iii) exogenously expressed ERG promotes CXCR4 expression; (iv) ERG is phosphorylated at Serine-81 and -215, by both IKK and Akt kinases, and Akt mediates CXCR4 expression; (v) ERG-induced CXCR4 drives CXCL12-dependent adhesion to fibronectin; and (vi) ERG and CXCR4 were coexpressed in human prostate cancer tissue, consistent with ERG-mediated transcriptional activation of CXCR4. These data demonstrate that ERG activates CXCR4 expression by binding to specific ERG/Ets responsive elements and via intracellular kinases that phosphorylate ERG at discrete serine residues. IMPLICATIONS: These findings provide a mechanistic link between TMPRSS2-ERG translocations and intracellular kinase-mediated phosphorylation of ERG on enhanced metastasis of tumor cells via CXCR4 expression and function in prostate cancer cells. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23918819      PMCID: PMC3901058          DOI: 10.1158/1541-7786.MCR-12-0705

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  54 in total

1.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

2.  The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.

Authors:  Manit Arya; Hitendra R H Patel; Claire McGurk; Roger Tatoud; Helmut Klocker; John Masters; Magali Williamson
Journal:  J Exp Ther Oncol       Date:  2004-12

3.  Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells.

Authors:  Yan-Xi Sun; Ming Fang; Jianhua Wang; Carlton R Cooper; Kenneth J Pienta; Russell S Taichman
Journal:  Prostate       Date:  2007-01-01       Impact factor: 4.104

4.  The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA-dependent and -independent manner.

Authors:  J P Basuyaux; E Ferreira; D Stéhelin; G Butticè
Journal:  J Biol Chem       Date:  1997-10-17       Impact factor: 5.157

5.  Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer.

Authors:  Takuya Akashi; Keiichi Koizumi; Koichi Tsuneyama; Ikuo Saiki; Yasuo Takano; Hideki Fuse
Journal:  Cancer Sci       Date:  2008-01-14       Impact factor: 6.716

6.  Delineation of TMPRSS2-ERG splice variants in prostate cancer.

Authors:  Ying Hu; Albert Dobi; Taduru Sreenath; Christopher Cook; Atekelt Y Tadase; Lakshmi Ravindranath; Jennifer Cullen; Bungo Furusato; Yongmei Chen; Rajesh L Thangapazham; Ahmed Mohamed; Chen Sun; Isabell A Sesterhenn; David G McLeod; Gyorgy Petrovics; Shiv Srivastava
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

7.  Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.

Authors:  Mingfang Ao; Omar E Franco; Dean Park; Dayanidhi Raman; Karin Williams; Simon W Hayward
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

8.  CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.

Authors:  Shailesh Singh; Udai P Singh; William E Grizzle; James W Lillard
Journal:  Lab Invest       Date:  2004-12       Impact factor: 5.662

9.  Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo.

Authors:  Yan-Xi Sun; Jingcheng Wang; Charles E Shelburne; Dennis E Lopatin; Arul M Chinnaiyan; Mark A Rubin; Kenneth J Pienta; Russell S Taichman
Journal:  J Cell Biochem       Date:  2003-06-01       Impact factor: 4.429

10.  Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.

Authors:  Lihong Yin; Pravin Rao; Paul Elson; Jianghua Wang; Michael Ittmann; Warren D W Heston
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

View more
  24 in total

1.  microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients.

Authors:  Ashraf Bakkar; Mohammed Alshalalfa; Lars F Petersen; Hatem Abou-Ouf; Amal Al-Mami; Samar A Hegazy; Felix Feng; Reda Alhajj; Krikor Bijian; Moulay A Alaoui-Jamali; Tarek A Bismar
Journal:  Mol Biol Rep       Date:  2016-02-23       Impact factor: 2.316

2.  MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation.

Authors:  Y Huang; J A I Thoms; M L Tursky; K Knezevic; D Beck; V Chandrakanthan; S Suryani; J Olivier; A Boulton; E N Glaros; S R Thomas; R B Lock; K L MacKenzie; J H Bushweller; J W H Wong; J E Pimanda
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

Review 3.  Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue.

Authors:  Jian-Hua Luo; Silvia Liu; Ze-Hua Zuo; Rui Chen; George C Tseng; Yan P Yu
Journal:  Am J Pathol       Date:  2015-05-09       Impact factor: 4.307

4.  Considering race and the potential for ERG expression as a biomarker for prostate cancer.

Authors:  Isaac J Powell; Gregory Dyson; Sreenivasa R Chinni; Aliccia Bollig-Fischer
Journal:  Per Med       Date:  2014       Impact factor: 2.512

Review 5.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

6.  The oncogenic transcription factor ERG represses the transcription of the tumour suppressor gene PTEN in prostate cancer cells.

Authors:  Patricia Adamo; Sean Porazinski; Shavanthi Rajatileka; Samantha Jumbe; Rachel Hagen; Man-Kim Cheung; Ian Wilson; Michael R Ladomery
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

7.  ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.

Authors:  Katelyn Powell; Louie Semaan; M Katie Conley-LaComb; Irfan Asangani; Yi-Mi Wu; Kevin B Ginsburg; Julia Williams; Jeremy A Squire; Krishna R Maddipati; Michael L Cher; Sreenivasa R Chinni
Journal:  Clin Cancer Res       Date:  2015-03-09       Impact factor: 12.531

8.  CXCR4 is highly expressed at the tumor front but not in the center of prostate cancers.

Authors:  Nicolas Barry Delongchamps; Frédéric Beuvon; Jacques R R Mathieu; Stéphanie Delmas; Isabelle Metzger; Hervé Prats; Florence Cabon
Journal:  World J Urol       Date:  2014-04-19       Impact factor: 4.226

Review 9.  Regulation of chemokine expression in the tumor microenvironment.

Authors:  Anton V Gorbachev; Robert L Fairchild
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

10.  Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.

Authors:  Yinhui Yang; Alexandra M Blee; Dejie Wang; Jian An; Yunqian Pan; Yuqian Yan; Tao Ma; Yundong He; Joseph Dugdale; Xiaonan Hou; Jun Zhang; S John Weroha; Wei-Guo Zhu; Y Alan Wang; Ronald A DePinho; Wanhai Xu; Haojie Huang
Journal:  Cancer Res       Date:  2017-10-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.